Plymouth

Esperion Gets Positive Results From New Study Of Cholesterol Drug

Esperion Therapeutics Inc. Friday announced “positive” results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.

WWJ Newsradio 950–2013/06/09

32 New Charter Schools Plan To Open In Michigan

Thirty-two new charter schools that meet “very specific educational needs” are scheduled to open in Michigan this fall.

WWJ Newsradio 950–2013/05/23

Esperion Files For $70M IPO

The Plymouth-based cholesterol drug developer Esperion Therapeutics Inc. has filed for an initial public stock offering with the federal Securities and Exchange Commission. Esperion is seeking to raise up to $70 million.

WWJ Newsradio 950–2013/05/15

Esperion Reports Cholesterol Cut Up To 43% In Diabetics On New Drug

Esperion Therapeutics’ proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.

WWJ Newsradio 950–2013/05/02

Rofin-Sinar Profit Falls On Flat Revenue

Rofin-Sinar Technologies Inc., the industrial laser maker with headquarters in Plymouth and in Hamburg, Germany, reported net income of $7.4 million or 26 cents a share in its second fiscal quarter ended March 31, down 6 percent from $8 million or 28 cents a share in the same quarter a year earlier.

WWJ Newsradio 950–2013/05/02